AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed glioblastoma multiforme, meeting 1 of the following criteria:
• * Phase I
• * In first or second recurrence or relapse
• * At least 1 measurable or evaluable enhancing lesion by gadolinium MRI (Gd-MRI) of the brain within the past 3 weeks
• * Phase II, group 1
• * In first or second recurrence or relapse by Gd-MRI of the brain within the past 3 weeks
• * Requires tumor biopsy OR surgical resection for tumor debulking or for confirmation of recurrence
• * Phase II, group 2
• * In first recurrence or relapse
• * At least 1 bidimensionally measurable enhancing lesion (≥ 1.5 cm\^2 using product of the largest perpendicular diameters) by Gd-MRI of the brain within the past 3 weeks
• Multifocal disease allowed
• PATIENT CHARACTERISTICS:
• Performance status
• Karnofsky 70-100%
• Life expectancy
• At least 12 weeks
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Hemoglobin ≥ 9 g/dL
• Platelet count ≥ 100,000/mm\^3
• Hepatic
• Bilirubin ≤ 1.5 times upper limit of normal (ULN)
• AST and ALT ≤ 2.5 times ULN
• No acute or chronic liver disease
• Renal
• Total calcium (corrected) normal\*
• Creatinine ≤ 1.5 times ULN OR
• Creatinine clearance ≥ 50 mL/min
• No proteinuria by dipstick OR
• Total urinary protein ≤ 500 mg AND creatinine clearance ≥ 50 mL/min by 24-hour urine collection
• No acute or chronic renal disease NOTE: \*Supplements allowed
• Cardiovascular
• LVEF ≥ 45% by MUGA or echocardiogram
• No complete left bundle branch block
• No requirement for a cardiac pacemaker
• No congenital long QT syndrome
• No ventricular or atrial tachyarrhythmias
• No clinically significant resting bradycardia, defined as \< 50 beats per minute
• QTc ≤ 480 msec by ECG
• No right bundle branch block and left anterior hemiblock (bifascicular block)
• No uncontrolled hypertension OR history of labile hypertension
• No unstable angina pectoris OR angina pectoris occurrence within the past 3 months
• No congestive heart failure
• No acute myocardial infarction within the past 3 months
• No history of poor compliance with an antihypertensive regimen
• No other impaired cardiac function or clinically significant cardiac disease
• Gastrointestinal
• No unresolved diarrhea ≥ grade 2
• No impairment of gastrointestinal (GI) function or GI disease that would significantly alter absorption of study drugs, including any of the following:
• * Ulcerative disease
• * Uncontrolled nausea
• * Vomiting
• * Malabsorption syndrome
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception
• Potassium normal\*
• Magnesium normal\*
• Phosphorus normal\*
• Cholesterol ≤ 300 mg/dL (treatment allowed)
• Triglycerides ≤ 2.5 times ULN (treatment allowed)
• No known HIV positivity
• No peripheral neuropathy ≥ grade 2
• No uncontrolled diabetes
• No active or uncontrolled infection
• No other severe and/or uncontrolled medical condition that would preclude study participation or compliance
• No contraindication to MRI, including any of the following:
• * Cardiac pacemaker
• * Ferromagnetic metal implants other than those approved as safe for use with magnetic resonance scanners (e.g., some types of aneurysm clips or shrapnel)
• * Claustrophobia
• * Obesity exceeding magnetic resonance equipment limits
• No other clinically significant primary malignancy requiring active intervention NOTE: \*Supplements allowed
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• More than 2 weeks since prior hematopoietic colony-stimulating factors (e.g., filgrastim \[G-CSF\] or sargramostim \[GM-CSF\]) except epoetin alfa
• More than 2 weeks since prior immunotherapy and recovered
• No concurrent biologic therapy
• No concurrent prophylactic hematopoietic growth factors (e.g., G-CSF or GM-CSF) unless approved by the study sponsor
• Chemotherapy
• More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered
• Prior polifeprosan 20 with carmustine implant (Gliadel® wafer) allowed
• No other concurrent chemotherapy
• Endocrine therapy
• Must be on stable or deceasing doses of steroids for at least 7 days before baseline Gd-MRI of the brain and before starting study drug
• No concurrent tamoxifen
• Radiotherapy
• More than 4 weeks since prior radiotherapy and recovered
• No concurrent radiotherapy
• Surgery
• More than 1 week since prior tumor biopsy
• More than 2 weeks since prior surgical resection
• More than 2 weeks since prior major non-CNS surgery and recovered
• No prior small bowel resection
• Other
• At least 2 weeks since prior and no concurrent enzyme-inducing anticonvulsant drugs
• More than 4 weeks since prior investigational drugs and recovered
• No prior epidermal growth factor receptor- or ErbB-2-directed therapy (phase II only)
• No prior vascular endothelial growth factor (VEGF) or VEGF receptor-directed therapy (phase II only)
• No prior mTOR-directed therapy (phase II only)
• No concurrent therapeutic warfarin
• No concurrent treatment with any medication that may prolong QT interval, including any of the following:
• * Quinidine
• * Procainamide
• * Disopyramide
• * Amiodarone
• * Sotalol
• * Bretylium
• * Ibutilide
• * Thioridazine
• * Mesoridazine
• * Chlorpromazine
• * Amitriptyline
• * Imipramine
• * Desipramine
• * Doxepin
• * Erythromycin
• * Clarithromycin
• * Ketoconazole
• * Halofantrine
• * Quinine
• * Chloroquine
• * Mefloquine
• * Moxifloxacin
• * Gatifloxacin
• * Pimozide
• * Risperidone
• * Ziprasidone
• * Venlafaxine
• * Maprotiline
• * Lithium
• * Pentamidine
• * Droperidol
• * Dolasetron
• No concurrent digoxin or verapamil
• No concurrent tacrolimus
• No other concurrent investigational agents